Chemotherapy Declination Associated With Increased Risk of Death Among Patients With Early-Stage HR+/HER2- BC and High RS
EMBER-3 Trial: Imlunestrant Improves PROs in ER+/HER2– Breast Cancer
Oral Paclitaxel Non-Inferior to IV Paclitaxel in HER2-Negative mBC